DE69813070D1 - Pharmazeutische Zubereitung zur oralen Anwendung enthaltend einen Histamin-Immunoglobulin Komplex - Google Patents
Pharmazeutische Zubereitung zur oralen Anwendung enthaltend einen Histamin-Immunoglobulin KomplexInfo
- Publication number
- DE69813070D1 DE69813070D1 DE69813070T DE69813070T DE69813070D1 DE 69813070 D1 DE69813070 D1 DE 69813070D1 DE 69813070 T DE69813070 T DE 69813070T DE 69813070 T DE69813070 T DE 69813070T DE 69813070 D1 DE69813070 D1 DE 69813070D1
- Authority
- DE
- Germany
- Prior art keywords
- diseases
- oral administration
- drug preparation
- preparation
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 5
- 229940079593 drug Drugs 0.000 abstract 5
- 208000023275 Autoimmune disease Diseases 0.000 abstract 2
- 108060003951 Immunoglobulin Proteins 0.000 abstract 2
- 102000018358 immunoglobulin Human genes 0.000 abstract 2
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 201000004624 Dermatitis Diseases 0.000 abstract 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 206010014950 Eosinophilia Diseases 0.000 abstract 1
- 206010021460 Immunodeficiency syndromes Diseases 0.000 abstract 1
- 208000030852 Parasitic disease Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 208000024780 Urticaria Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- 208000001319 vasomotor rhinitis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9031311A JPH10212246A (ja) | 1997-01-30 | 1997-01-30 | 経口投与用製剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69813070D1 true DE69813070D1 (de) | 2003-05-15 |
DE69813070T2 DE69813070T2 (de) | 2003-12-04 |
Family
ID=12327752
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69813070T Expired - Fee Related DE69813070T2 (de) | 1997-01-30 | 1998-01-30 | Pharmazeutische Zubereitung zur oralen Anwendung enthaltend einen Histamin-Immunoglobulin Komplex |
Country Status (10)
Country | Link |
---|---|
US (1) | US6187803B1 (de) |
EP (1) | EP0864323B1 (de) |
JP (1) | JPH10212246A (de) |
KR (1) | KR100533399B1 (de) |
CN (1) | CN1167466C (de) |
AT (1) | ATE236615T1 (de) |
AU (1) | AU735950B2 (de) |
CA (1) | CA2228017A1 (de) |
DE (1) | DE69813070T2 (de) |
TW (1) | TW544316B (de) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6566386B2 (en) | 1993-08-09 | 2003-05-20 | Nippon Zoki Pharmaceutical Co., Ltd. | Immunomodulating and antiinflammatory agent |
JP2000143536A (ja) | 1998-11-13 | 2000-05-23 | Nippon Zoki Pharmaceut Co Ltd | 抗浮腫剤 |
JP2000143537A (ja) * | 1998-11-13 | 2000-05-23 | Nippon Zoki Pharmaceut Co Ltd | 細胞接着分子発現抑制剤 |
CA2462682A1 (en) * | 2001-10-04 | 2003-04-10 | Protein Therapeutics, Inc. | The use of gammaglobulin for the treatment of immune-mediated diseases |
PT2891666T (pt) | 2002-10-16 | 2017-09-22 | Purdue Pharma Lp | Anticorpos que se ligam ca 125/0722p associado a células e métodos para a sua utilização |
WO2006099175A2 (en) * | 2005-03-11 | 2006-09-21 | Euro-Celtique S.A. | Compositions comprising an anti-ca125 antibody and a cytotoxic compound and their use for the treatment of cancer |
KR100723251B1 (ko) * | 2005-03-18 | 2007-05-29 | 전숙영 | 알레르기 질환의 치료를 위한 약학적 조성물, 그의 용도 및알레르기 질환의 치료방법 |
RU2309732C1 (ru) * | 2006-03-13 | 2007-11-10 | Олег Ильич Эпштейн | Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата |
KR100756974B1 (ko) * | 2006-03-16 | 2007-09-07 | 전숙영 | 알레르기 질환 및 만성염증성 질환의 치료를 위한 약학적 조성물 및 키트 |
WO2008139487A1 (en) * | 2007-05-10 | 2008-11-20 | Rajesh Shah | Homeopathy-based formulation |
US20130039903A1 (en) * | 2010-04-23 | 2013-02-14 | Probiotec Limited | Eczema treatment |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3873697A (en) | 1972-11-11 | 1975-03-25 | Mack Chem Pharm | Histamine antigen |
US4705685A (en) * | 1982-05-17 | 1987-11-10 | Mcmichael John | Methods and materials for treatment of disease states involving immunological factors |
US4704273A (en) | 1982-05-17 | 1987-11-03 | Mcmichael John | Methods and materials for treatment of rheumatoid arthritis |
US4705687A (en) | 1985-06-17 | 1987-11-10 | Ortho Pharmaceutical (Canada) Ltd. | Treatment of autoimmune diseases such as rheumatoid arthritis with suppressor factor |
US5112738A (en) | 1985-07-03 | 1992-05-12 | Miles Inc. | Histamine derivatives, immunogen conjugates and antibodies raised thereto |
US4812449A (en) | 1986-07-03 | 1989-03-14 | Scripps Clinic And Research Foundation | In situ active compound assembly |
US5244902A (en) | 1989-08-21 | 1993-09-14 | Beth Israel Hospital Association | Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses |
IT1237475B (it) | 1989-10-06 | 1993-06-07 | Allergeni modificati chimicamente e procedimento per la loro preparazione | |
US5192773A (en) | 1990-07-02 | 1993-03-09 | Vertex Pharmaceuticals, Inc. | Immunosuppressive compounds |
JP3193205B2 (ja) * | 1993-08-09 | 2001-07-30 | 日本臓器製薬株式会社 | 好酸球増多抑制剤 |
JPH0959180A (ja) | 1995-08-11 | 1997-03-04 | Nippon Zoki Pharmaceut Co Ltd | 活性化免疫グロブリン |
-
1997
- 1997-01-30 JP JP9031311A patent/JPH10212246A/ja not_active Withdrawn
-
1998
- 1998-01-23 CN CNB981051375A patent/CN1167466C/zh not_active Expired - Fee Related
- 1998-01-23 TW TW087100904A patent/TW544316B/zh not_active IP Right Cessation
- 1998-01-23 KR KR1019980002115A patent/KR100533399B1/ko not_active IP Right Cessation
- 1998-01-26 US US09/013,202 patent/US6187803B1/en not_active Expired - Fee Related
- 1998-01-26 CA CA002228017A patent/CA2228017A1/en not_active Abandoned
- 1998-01-29 AU AU52790/98A patent/AU735950B2/en not_active Ceased
- 1998-01-30 DE DE69813070T patent/DE69813070T2/de not_active Expired - Fee Related
- 1998-01-30 EP EP98101614A patent/EP0864323B1/de not_active Expired - Lifetime
- 1998-01-30 AT AT98101614T patent/ATE236615T1/de not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE69813070T2 (de) | 2003-12-04 |
EP0864323A1 (de) | 1998-09-16 |
KR100533399B1 (ko) | 2007-03-15 |
EP0864323B1 (de) | 2003-04-09 |
KR19980070794A (ko) | 1998-10-26 |
AU5279098A (en) | 1998-08-06 |
CA2228017A1 (en) | 1998-07-30 |
US6187803B1 (en) | 2001-02-13 |
JPH10212246A (ja) | 1998-08-11 |
ATE236615T1 (de) | 2003-04-15 |
AU735950B2 (en) | 2001-07-19 |
CN1167466C (zh) | 2004-09-22 |
CN1192929A (zh) | 1998-09-16 |
TW544316B (en) | 2003-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY2013041I1 (el) | Φαρμακευτικες συνθεσεις περιλαμβανοντας δεξτρομεθορφανη και κινιδινη για την αγωγη νευρολογικων διαταραχων | |
DE69813070D1 (de) | Pharmazeutische Zubereitung zur oralen Anwendung enthaltend einen Histamin-Immunoglobulin Komplex | |
ATE311903T1 (de) | Verfahren, zusammensetzungen und kits zur erhöhung der oralen bioverfügbarkeit von pharmazeutika | |
CY1115484T1 (el) | Ενωσεις, συνθεσεις και μεθοδοι για την θεραπεια αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων, οπως νοσος alzheimer, διαβητης τυπου 2 και νοσος parkinson | |
TR200100377T2 (tr) | Aß Protein üretimi inhibitörleri olarak sukinoilamino laktamlar. | |
DE69738948D1 (de) | Il-1-inhibitor in kombinationstherapie zur behandlung il-1-vermittelter krankheiten | |
TW200607807A (en) | Macrocyclic beta-secretase inhibitors | |
HUP0204023A2 (hu) | Pirrolidinacetamidszármazék alkalmazása önmagában vagy kombinációban központi idegrendszeri zavarok kezelésére és ezeket tartalmazó gyógyszerkészítmények | |
EA200701296A1 (ru) | 3,5-дизамещенные и 3,5,7-тризамещенные 3h-оксазоло- и 3h-тиазоло[4,5-d] пиримидин-2-оны и их пролекарства | |
TW200621249A (en) | Substituted amide beta secretase inhibitors | |
ATE141599T1 (de) | Kondensierte polyzyklische verbindungen, zusammenstellungen, verfahren zur herstellung und deren anwendung als paf-antagonistische, antihistaminische und/oder anti-inflammatorische agenzien | |
DK0639079T3 (da) | Fremgangsmåder til behandling af interleukin-1- og tumornekrosefaktor-medierede sygdomme | |
ATE192655T1 (de) | Verwendung von histamin-gamma-globulin zur herstellung eines immunomodulierenden und antiinflammatorischen agens | |
DE60237363D1 (de) | Verfahren zur behandlung von entzündlichen erkrankungen des verdauungstrakts mit topisch wirksamen kortikosteroiden | |
HUP0401614A2 (hu) | PDE4 inhibitort és antikolinerg hatóanyagot tartalmazó gyógyszerkészítmények és alkalmazásuk | |
JP2006511555A5 (de) | ||
HUP0202862A2 (hu) | A loteprednol és antihisztaminok új kombinációját tartalmazó gyógyszerkészítmény | |
WO1992012715A3 (en) | The use of loperamide and related compounds for treatment of respiratory disease symptoms | |
EA200400549A1 (ru) | Лечение сепсиса введением малых доз ингибитора пути тканевого фактора (tfpi) | |
ATE469907T1 (de) | Triptolid-analoga zur behandlung von autoimmunkranheiten und entzündungen | |
WO2005041864A3 (en) | Combination of cyclooxygenase-2 inhibitor and phosphodiesterase 4 inhibitor and method | |
CA2433833A1 (en) | Use of flumazenil in developing a drug for the treatment of alcohol dependence | |
HUP0400115A2 (hu) | Gyógyászati készítmény fulvesztrant intramuszkuláris beadására | |
EA200000242A1 (ru) | Применение фанхинона для лечения болезни альцгеймера | |
PH12021551152A1 (en) | Use of glutarimide derivative for overcoming steroid resistance and treating diseases associated with aberrant interferon gamma signaling |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |